Effect of medicines management versus standard care on readmissions in multimorbid patients: a randomised controlled trial

Marianne Lea, Morten Mowé, Espen Molden, Kristin Kvernrød, Eva Skovlund, Liv Mathiesen, Marianne Lea, Morten Mowé, Espen Molden, Kristin Kvernrød, Eva Skovlund, Liv Mathiesen

Abstract

Objective: To investigate the effect of pharmacist-led medicines management in multimorbid, hospitalised patients on long-term hospital readmissions and survival.

Design: Parallel-group, randomised controlled trial.

Setting: Recruitment from an internal medicine hospital ward in Oslo, Norway. Patients were enrolled consecutively from August 2014 to the predetermined target number of 400 patients. The last participant was enrolled March 2016. Follow-up until 31 December 2017, that is, 21-40 months.

Participants: Acutely admitted multimorbid patients ≥18 years, using minimum four regular drugs from minimum two therapeutic classes. 399 patients were randomly assigned, 1:1, to the intervention or control group. After excluding 11 patients dying in-hospital and 2 erroneously included, the primary analysis comprised 386 patients (193 in each group) with median age 79 years (range 23-96) and number of diseases 7 (range 2-17).

Intervention: Intervention patients received pharmacist-led medicines management comprising medicines reconciliation at admission, repeated medicines reviews throughout the stay and medicines reconciliation and tailored information at discharge, according to the integrated medicines management model. Control patients received standard care.

Primary and secondary outcome measures: The primary endpoint was difference in time to readmission or death within 12 months. Overall survival was a priori the clinically most important secondary endpoint.

Results: Pharmacist-led medicines management had no significant effect on the primary endpoint time to readmission or death within 12 months (median 116 vs 184 days, HR 0.82, 95% CI 0.64 to 1.04, p=0.106). A statistically significantly increased overall survival was observed during 21-40 months follow-up (HR 0.66, 95% CI 0.48 to 0.90, p=0.008).

Conclusions: Pharmacist-led medicines management had no statistically significant effect on time until readmission or death. A statistically significant increased overall survival was seen. Further studies should be conducted to investigate the effect of such an intervention on a larger scale.

Trial registration number: NCT02336113.

Keywords: clinical pharmacology; internal medicine; public health; quality in health care; therapeutics.

Conflict of interest statement

Competing interests: ML received Ph.D. funding from the South-Eastern Norway Regional Health Authority (grant number 12/00718).

© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Graphical depiction of the study design, inspired by Perera et al. Objects are represented by squares and activities by circles.
Figure 2
Figure 2
Patient flow.
Figure 3
Figure 3
(A) Time to first hospital readmission or death in the intervention versus the control group. (B) Overall survival in the intervention versus the control group.

References

    1. Uijen AA, van de Lisdonk EH. Multimorbidity in primary care: prevalence and trend over the last 20 years. Eur J Gen Pract 2008;14:28–32. 10.1080/13814780802436093
    1. Jurevicienė E, Onder G, Visockienė Ž, et al. . Does multimorbidity still remain a matter of the elderly: Lithuanian national data analysis. Health Policy 2018;122:681–6. 10.1016/j.healthpol.2018.03.003
    1. Mercer S, Salisbury C, Fortin M. Abc of multimorbidity. first ED. John Wiley & Sons, 2014.
    1. Marengoni A, Angleman S, Melis R, et al. . Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev 2011;10:430–9. 10.1016/j.arr.2011.03.003
    1. Roberts KC, Rao DP, Bennett TL, et al. . Prevalence and patterns of chronic disease multimorbidity and associated determinants in Canada. Health Promot Chronic Dis Prev Can 2015;35:87–94. 10.24095/hpcdp.35.6.01
    1. Brett T, Arnold-Reed DE, Popescu A, et al. . Multimorbidity in patients attending 2 Australian primary care practices. Ann Fam Med 2013;11:535–42. 10.1370/afm.1570
    1. Nobili A, Marengoni A, Tettamanti M, et al. . Association between clusters of diseases and polypharmacy in hospitalized elderly patients: results from the REPOSI study. Eur J Intern Med 2011;22:597–602. 10.1016/j.ejim.2011.08.029
    1. DuGoff EH, Canudas-Romo V, Buttorff C, et al. . Multiple chronic conditions and life expectancy: a life table analysis. Med Care 2014;52:688–94. 10.1097/MLR.0000000000000166
    1. Lehnert T, Heider D, Leicht H, et al. . Review: health care utilization and costs of elderly persons with multiple chronic conditions. Med Care Res Rev 2011;68:387–420. 10.1177/1077558711399580
    1. Boyd CM, Darer J, Boult C, et al. . Clinical practice guidelines and quality of care for older patients with multiple comorbid diseases: implications for pay for performance. JAMA 2005;294:716–24. 10.1001/jama.294.6.716
    1. Tinetti ME, Fried TR, Boyd CM. Designing health care for the most common chronic condition--multimorbidity. JAMA 2012;307:2493–4. 10.1001/jama.2012.5265
    1. Barnett K, Mercer SW, Norbury M, et al. . Epidemiology of multimorbidity and implications for health care, research, and medical education: a cross-sectional study. Lancet 2012;380:37–43. 10.1016/S0140-6736(12)60240-2
    1. Köberlein-Neu J, Mennemann H, Hamacher S, et al. . Interprofessional medication management in patients with multiple morbidities. Dtsch Arztebl Int 2016;113:741–8. 10.3238/arztebl.2016.0741
    1. Fiß T, Meinke-Franze C, van den Berg N, et al. . Effects of a three Party healthcare network on the incidence levels of drug related problems. Int J Clin Pharm 2013;35:763–71. 10.1007/s11096-013-9804-x
    1. Al Hamid A, Ghaleb M, Aljadhey H, et al. . A systematic review of hospitalization resulting from medicine-related problems in adult patients. Br J Clin Pharmacol 2014;78:202–17. 10.1111/bcp.12293
    1. Gustafsson M, Sjölander M, Pfister B, et al. . Drug-Related hospital admissions among old people with dementia. Eur J Clin Pharmacol 2016;72:1143–53. 10.1007/s00228-016-2084-3
    1. Rafter N, Hickey A, Conroy RM, et al. . The Irish national adverse events study (INAES): the frequency and nature of adverse events in Irish hospitals-a retrospective record review study. BMJ Qual Saf 2017;26:111–9. 10.1136/bmjqs-2015-004828
    1. Lea M, Rognan SE, Koristovic R, et al. . Severity and management of drug-drug interactions in acute geriatric patients. Drugs Aging 2013;30:721–7. 10.1007/s40266-013-0091-y
    1. Hohmann C, Neumann-Haefelin T, Klotz JM, et al. . Drug-Related problems in patients with ischemic stroke in hospital. Int J Clin Pharm 2012;34:828–31. 10.1007/s11096-012-9690-7
    1. El Morabet N, Uitvlugt EB, van den Bemt BJF, et al. . Prevalence and preventability of drug-related Hospital readmissions: a systematic review. J Am Geriatr Soc 2018;66:602–8. 10.1111/jgs.15244
    1. Schwab C, Korb-Savoldelli V, Escudie JB, et al. . Iatrogenic risk factors associated with Hospital readmission of elderly patients: a matched case-control study using a clinical data Warehouse. J Clin Pharm Ther 2018;43:393–400. 10.1111/jcpt.12670
    1. Christensen M, Lundh A. Medication review in hospitalised patients to reduce morbidity and mortality. Cochrane Database Syst Rev 2016;2:Cd008986. 10.1002/14651858.CD008986.pub3
    1. Scullin C, Scott MG, Hogg A, et al. . An innovative approach to integrated medicines management. J Eval Clin Pract 2007;13:781–8. 10.1111/j.1365-2753.2006.00753.x
    1. Midlöv P, Holmdahl L, Eriksson T, et al. . Medication report reduces number of medication errors when elderly patients are discharged from hospital. Pharm World Sci 2008;30:92–8. 10.1007/s11096-007-9149-4
    1. Scullin C, Hogg A, Luo R, et al. . Integrated medicines management - can routine implementation improve quality? J Eval Clin Pract 2012;18:807–15. 10.1111/j.1365-2753.2011.01682.x
    1. Midlöv P, Deierborg E, Holmdahl L, et al. . Clinical outcomes from the use of medication report when elderly patients are discharged from hospital. Pharm World Sci 2008;30:840–5. 10.1007/s11096-008-9236-1
    1. Bergkvist A, Midlöv P, Höglund P, et al. . Improved quality in the hospital discharge summary reduces medication errors--LIMM: Landskrona Integrated Medicines Management. Eur J Clin Pharmacol 2009;65:1037–46. 10.1007/s00228-009-0680-1
    1. Alassaad A, Bertilsson M, Gillespie U, et al. . The effects of pharmacist intervention on emergency department visits in patients 80 years and older: subgroup analyses by number of prescribed drugs and appropriate prescribing. PLoS One 2014;9:e111797. 10.1371/journal.pone.0111797
    1. Perera R, Heneghan C, Yudkin P. Graphical method for depicting randomised trials of complex interventions. BMJ 2007;334:127–9. 10.1136/bmj.39045.396817.68
    1. World Health Organization . Collaborating centre for drug statistics methodology. ATC index with DDDs. Available: [Accessed 20 Sep 2018].
    1. Wallace E, McDowell R, Bennett K, et al. . Comparison of count-based multimorbidity measures in predicting emergency admission and functional decline in older community-dwelling adults: a prospective cohort study. BMJ Open 2016;6:e013089. 10.1136/bmjopen-2016-013089
    1. Nilsson N, Lea M, Lao Y, et al. . Medication discrepancies revealed by medication reconciliation and their potential short-term and long-term effects: a Norwegian multicentre study carried out on internal medicine wards. European Journal of Hospital Pharmacy 2015;22:298–303. 10.1136/ejhpharm-2015-000686
    1. Parmaceutical Care Network Europe (PCNE) . Classification for drug related problems V 6.2. Available: [Accessed 3 April 2018].
    1. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31–41. 10.1159/000180580
    1. Salazar DE, Corcoran GB. Predicting creatinine clearance and renal drug clearance in obese patients from estimated fat-free body mass. Am J Med 1988;84:1053–60. 10.1016/0002-9343(88)90310-5
    1. Charlson ME, Pompei P, Ales KL, et al. . A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–83. 10.1016/0021-9681(87)90171-8
    1. Lea M, Mowe M, Mathiesen L, et al. . Prevalence and risk factors of drug-related hospitalizations in multimorbid patients admitted to an internal medicine ward. PLoS One 2019;14:e0220071. 10.1371/journal.pone.0220071
    1. Gail MH. Applicability of sample size calculations based on a comparison of proportions for use with the logrank test. Control Clin Trials 1985;6:112–9. 10.1016/0197-2456(85)90116-3
    1. Fine JP, Gray RJ. A proportional hazards model for the Subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509. 10.1080/01621459.1999.10474144
    1. Gillespie U, Alassaad A, Henrohn D, et al. . A comprehensive pharmacist intervention to reduce morbidity in patients 80 years or older: a randomized controlled trial. Arch Intern Med 2009;169:894–900. 10.1001/archinternmed.2009.71
    1. Ravn-Nielsen LV, Duckert M-L, Lund ML, et al. . Effect of an in-hospital multifaceted clinical pharmacist intervention on the risk of readmission. JAMA Intern Med 2018;178:375–82. 10.1001/jamainternmed.2017.8274
    1. Makowsky MJ, Koshman SL, Midodzi WK, et al. . Capturing outcomes of clinical activities performed by a rounding pharmacist practicing in a team environment: the COLLABORATE study [NCT00351676]. Med Care 2009;47:642–50. 10.1097/MLR.0b013e3181926032
    1. Ravn-Nielsen LV, Duckert M-L, Lund ML, et al. . Effect of an in-hospital multifaceted clinical pharmacist intervention on the risk of readmission: a randomized clinical trial. JAMA Intern Med 2018;178:375–82. 10.1001/jamainternmed.2017.8274
    1. Baker M, Bell CM, Xiong W, et al. . Do combined pharmacist and prescriber efforts on medication reconciliation reduce Postdischarge patient emergency department visits and hospital readmissions? J Hosp Med 2018;13:152–7. 10.12788/jhm.2857
    1. Craig P, Dieppe P, Macintyre S, et al. . Developing and evaluating complex interventions: the new medical Research Council guidance. BMJ 2008;337:a1655. 10.1136/bmj.a1655
    1. Richards D, Hallberg IR. Complex interventions in health. An overview of research metods. Routledge, 2015.
    1. Fernandes O. Medication reconciliation in the hospital: what, why, where, when, who and how? Healthc Q 2012;15 Spec No:42–9. 10.12927/hcq.2012.22842
    1. Griese-Mammen N, Hersberger KE, Messerli M, et al. . PCNE definition of medication review: reaching agreement. Int J Clin Pharm 2018;40:1199–208. 10.1007/s11096-018-0696-7

Source: PubMed

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

3
Abonner